MarketCap
Facebook
X
Telegram
Xenetic Biosciences Balance Sheet 2025-2011 | XBIO
Brief overview of Xenetic Biosciences's balance sheet structure
The review uses the five latest available annual reports between 2021 and 2025.
Assets fell from $19.8 million to $8.4 million. This may reflect either deliberate optimization or a reduction in business scale.
Liability growth of -31.9% exceeded asset growth of -57.8%, increasing reliance on outside funding.
Equity funds 88.4% of assets versus 92.8% initially. This creates a conservative balance sheet structure.
The cash reserve occupies 94.3% of the balance sheet, previously 92.1%. It is one marker of short-term resilience.
The accumulated result is -$199.9 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Xenetic Biosciences has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.
Annual Balance Sheet Xenetic Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -11.5 M | -10.4 M | -572 K | -5.53 M | -4.05 M | 263 K | -2.11 M | 160 K | 181 K | 203 K |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | 213 K | 213 K | 213 K |
Total Non Current Liabilities |
- | - | - | - | - | 27 K | 2.92 M | 2.92 M | 2.92 M | 2.94 M | 2.96 M | 3.14 M | 213 K | 213 K | 213 K |
Total Current Liabilities |
968 K | 894 K | 810 K | 1.07 M | 1.42 M | 937 K | 1.42 M | 1.6 M | 1.94 M | 1.87 M | 7.34 M | 2.7 M | 3.59 M | 1.4 M | - |
Total Liabilities |
968 K | 894 K | 810 K | 1.07 M | 1.42 M | 964 K | 4.33 M | 4.52 M | 4.86 M | 4.8 M | 10.3 M | 5.84 M | 669 K | 417 K | 221 K |
Retained Earnings |
-200 M | -197 M | -193 M | -189 M | -183 M | -177 M | -166 M | -153 M | -146 M | -142 M | -88.1 M | -75.6 M | -317 K | -138 K | -8.24 K |
Total Assets |
8.36 M | 6.9 M | 10.6 M | 14.7 M | 19.8 M | 13.2 M | 21.5 M | 14.4 M | 19.2 M | 21 M | 16.9 M | 16.3 M | 487 K | 324 K | 222 K |
Cash and Cash Equivalents |
7.88 M | 6.17 M | 8.98 M | 13.1 M | 18.2 M | 11.5 M | 10.4 M | 572 K | 5.53 M | 4.05 M | 132 K | 2.51 M | 4.84 M | 11.1 M | 17.1 M |
Book Value |
7.4 M | 6.01 M | 9.8 M | 13.6 M | 18.4 M | 12.2 M | 17.2 M | 9.91 M | 14.3 M | 16.2 M | 6.61 M | 10.5 M | -182 K | -92.9 K | 1.76 K |
Total Shareholders Equity |
7.4 M | 6.01 M | 9.8 M | 13.6 M | 18.4 M | 12.2 M | 17.2 M | 9.91 M | 14.3 M | 16.2 M | 6.61 M | 10.5 M | 12.6 M | 20.8 M | 14.8 M |
All numbers in USD currency
Quarterly Balance Sheet Xenetic Biosciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.96 K | 17.6 K | 27 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 213 K | - | - | - | - | - | - | - | - | - | - | - | 213 K | 213 K | 213 K | 213 K | 213 K | 213 K | 213 K | - | 213 K | 213 K | - |
Total Liabilities |
958 K | 1.11 M | 903 K | 668 K | 894 K | 1.01 M | 1.59 M | 716 K | 810 K | 1.07 M | 871 K | 856 K | 1.07 M | 1.05 M | 1.28 M | 1.06 M | 1.42 M | 1.12 M | 966 K | 816 K | 964 K | 964 K | 964 K | 964 K | 4.33 M | 4.33 M | 4.33 M | 4.33 M | 4.52 M | 4.52 M | 4.52 M | 4.52 M | 4.86 M | 4.86 M | 4.86 M | 4.86 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 5.84 M | 5.84 M | 5.84 M | 5.84 M | 6.85 M | 6.85 M | 6.85 M | 6.85 M | 4.59 M | 417 K | 417 K | 459 K | - | 221 K | - | - |
Retained Earnings |
-200 M | -199 M | -199 M | -198 M | -197 M | -196 M | -196 M | -194 M | -193 M | -192 M | -191 M | -190 M | -189 M | -188 M | -187 M | -184 M | -183 M | -181 M | -179 M | -178 M | -177 M | -177 M | -177 M | -177 M | -166 M | -166 M | -166 M | -166 M | -153 M | -153 M | -153 M | -153 M | -146 M | -146 M | -146 M | -146 M | -142 M | -142 M | -142 M | -142 M | -88.1 M | -88.1 M | -88.1 M | -88.1 M | -75.6 M | -75.6 M | -75.6 M | -75.6 M | -58.3 M | -58.3 M | -58.3 M | -58.3 M | -49.7 M | -228 K | - | - | - | - | - | - |
Total Assets |
7.91 M | 5.07 M | 5.35 M | 5.79 M | 6.9 M | 8.05 M | 9.03 M | 9.39 M | 10.6 M | 12 M | 12.7 M | 13.7 M | 14.7 M | 15.6 M | 16.5 M | 18 M | 19.8 M | 21.3 M | 10.9 M | 11.8 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 21.5 M | 21.5 M | 21.5 M | 21.5 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 21 M | 21 M | 21 M | 21 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 25.4 M | 324 K | 324 K | 352 K | - | 222 K | 222 K | - |
Cash and Cash Equivalents |
7.35 M | 4.12 M | 4.78 M | 5.16 M | 6.17 M | 6.84 M | 7.3 M | 7.82 M | 8.98 M | 9.78 M | 10.7 M | 12 M | 13.1 M | 13.8 M | 14.9 M | 16.2 M | 18.2 M | 19.7 M | 9.28 M | 10 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 572 K | 572 K | 572 K | 572 K | 5.53 M | 5.53 M | 5.53 M | 5.53 M | 4.05 M | 4.05 M | 4.05 M | 4.05 M | 132 K | 132 K | 132 K | 132 K | 2.51 M | 2.51 M | 2.51 M | 2.51 M | 4.84 M | 4.84 M | 4.84 M | 4.84 M | 11.1 M | 32 K | 32 K | 32 K | 17.1 M | 10 K | 10 K | - |
Book Value |
6.95 M | 3.96 M | 4.45 M | 5.12 M | 6.01 M | 7.04 M | 7.45 M | 8.68 M | 9.8 M | 10.9 M | 11.9 M | 12.9 M | 13.6 M | 14.5 M | 15.2 M | 16.9 M | 18.4 M | 20.2 M | 9.95 M | 10.9 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 9.91 M | 9.91 M | 9.91 M | 9.91 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 6.61 M | 6.61 M | 6.61 M | 6.61 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 20.8 M | -92.9 K | -92.9 K | -107 K | - | 1.76 K | 222 K | - |
Total Shareholders Equity |
6.95 M | 3.96 M | 4.45 M | 5.12 M | 6.01 M | 7.04 M | 7.45 M | 8.68 M | 9.8 M | 10.9 M | 11.9 M | 12.9 M | 13.6 M | 14.5 M | 15.2 M | 16.9 M | 18.4 M | 20.2 M | 9.95 M | 10.9 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 9.91 M | 9.91 M | 9.91 M | 9.91 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 6.61 M | 6.61 M | 6.61 M | 6.61 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 20.8 M | -92.9 K | -92.9 K | -107 K | 14.8 M | -92.9 K | 1.76 K | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Xenetic Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
China
France
Singapore
Britain
Germany
Israel
Russia
Belgium
